JCJie Chen

Jie Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jie Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Mengxi Huang

    Department of Medical Oncology Medical School Affiliated Jinling Hospital Nanjing University Nanjing Jiangsu Province China

    3 shared publications
  • Zengjie Lei

    Department of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China

    3 shared publications
  • Haimei Feng

    Department of Medical Oncology Jinling Clinical Medical College Nanjing University of Chinese Medicine Nanjing Jiangsu Province China

    2 shared publications
  • Siqi Sheng

    Department of Medical Oncology Medical School Affiliated Jinling Hospital Nanjing University Nanjing Jiangsu Province China

    2 shared publications
  • Xiaoming Bai

    Department of Medical Oncology Jinling Clinical Medical College Nanjing University of Chinese Medicine Nanjing Jiangsu Province China

    2 shared publications
  • Yiting Wang

    Department of Medical Oncology Medical School Affiliated Jinling Hospital Nanjing University Nanjing Jiangsu Province China

    2 shared publications

Latest Publications

  • Open Access

    MZF1 Inhibits TGFβ‐1/SMAD Signaling by Transcriptionally Activating SnoN to Augment Tumorigenic Potential in Colon Cancer

    by Siqi Sheng, Mengxi Huang, Yiting Wang, Hongyu Wang, Haimei Feng, Xiaoming Bai, Jie Chen, Ke Xu, Xiaoyuan Chu, Zengjie Lei

    Colon cancer progression is associated with transcriptional and signaling abnormalities. MZF1, linked to leukemogenesis, has an unclear role in colon cancer. This study examined its function in colon tumorigenesis and signaling‐targeted therapies. Multi‐omics (RNA‐seq, CUT&Tag) identified MZF1 targets, validated in vitro/in vivo using xenografts and epithelial‐specific MZF1 knockout mice. Virtual screening found MZF1 inhibitors. MZF1 activated SnoN transcription, suppressing TGF‐β/SMAD signaling. Overexpression enhanced proliferation and colony formation; knockdown reversed these. In vivo, MZF1‐overexpressing xenografts grew faster with more Ki67+ cells, while MZF1 −/− mice had reduced tumor burden. Organoids from MZF1 −/− mice grew poorly. 10Panx Acetate, an MZF1 inhibitor, disrupted MZF1‐SnoN interaction, inhibiting cell and xenograft growth. Our results indicate MZF1 as a key colon cancer regulator via SnoN‐mediated TGF‐β pathway suppression and suggest 10Panx Acetate for precision therapy. MZF1/SnoN co‐expression may predict aggressive disease.

  • Open Access

    Effect of elevated CEA levels on the outcome of colorectal cancer patients with different histopathologic types:A SEER population-based study

    by Siqi Sheng, Xiaoming Bai, Yiting Wang, Haimei Feng, Jie Chen, Yitian Chen, Mengxi Huang, Zengjie Lei, Xiaoyuan Chu

    Limited and contradictory evidence has been reported regarding the prognostic effects of carcinoembryonic antigen (CEA) on the prognosis and metastasis of classical adenocarcinoma (CA), mucinous adenocarcinoma (MA), and signet-ring cell carcinoma (SRCC) in colorectal cancer (CRC) patients. We investigated the associations between histological subtypes and preoperative serum CEA levels in determining the oncologic outcomes of CRC patients. A total of 47,692 patients with clearly diagnosed CRC were selected from the Surveillance, Epidemiology, and End Results (SEER) database and divided into two cohorts based on serum CEA levels: CEA-normal (C0) and CEA-elevated (C1). Chi-square analysis revealed a correlation between CEA levels and histological classification. We then included a newly defined interaction variable (H&CEA) in the Cox regression analysis, which demonstrated that this variable could serve as an independent prognostic factor (P < 0.001). CA, in the context of elevated serum CEA levels, differed from the other two histopathological types, showing unexpectedly higher risks for both overall survival (OS) (HR = 1.70, 95% CI = 1.65–1.75, P < 0.001) and cancer-specific survival (CSS) (HR = 1.78, 95% CI = 1.72–1.85, P < 0.001). Furthermore, elevated CEA levels significantly increased the proportion of liver metastases in the CA group (25.43% vs 3.95%, P < 0.001). The interaction variable H&CEA can be used as an independent prognostic factor for CRC and should be considered in the diagnosis of CRC and the development of personalized treatment plans. Additionally, in the context of elevated CEA levels, CA is associated with poor prognosis and increased liver metastases. This CRC subgroup warrants special clinical attention from oncologists.


  • Open Access

    The involvement of E3 ubiquitin ligases in the development and progression of colorectal cancer

    by Jie Chen, Haimei Feng, Yiting Wang, Xiaoming Bai, Siqi Sheng, Huiyu Li, Mengxi Huang, Xiaoyuan Chu, Zengjie Lei

    To date, colorectal cancer (CRC) still has limited therapeutic efficacy and poor prognosis and there is an urgent need for novel targets to improve the outcome of CRC patients. The highly conserved ubiquitination modification mediated by E3 ubiquitin ligases is an important mechanism to regulate the expression and function of tumor promoters or suppressors in CRC. In this review, we provide an overview of E3 ligases in modulating various biological processes in CRC, including proliferation, migration, stemness, metabolism, cell death, differentiation and immune response of CRC cells, emphasizing the pluripotency of E3 ubiquitin ligases. We further focus on the role of E3 ligases in regulating vital cellular signal pathways in CRC, such as Wnt/β-catenin pathway and NF-κB pathway. Additionally, considering the potential of E3 ligases as novel targets in the treatment of CRC, we discuss what aspects of E3 ligases can be utilized and exploited for efficient therapeutic strategies.